Plerixafor and G-CSF

PreclinicalSmall molecule

UUniversity of Liverpool

Plerixafor and G-CSF is one of 24 small molecule programs targeting Transplantation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TransplantationCompleted

TransplantationPreclinical

Completed

Competition

Competitive Landscape

28 competitors in Transplantation

#DrugCompanyPhaseTrials

Atgam

Novartis

Phase 3

5 2

Rituxan

Roche

Phase 3

5 3

Prograf

VVeloxis Pharmaceuticals

Phase 3

12 4

Olumiant

Eli Lilly

Phase 3

1 5

Fludara

Sanofi

Phase 2

14 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

3 7

Cytoxan

BBaxter Healthcare Corporation

Phase 2

14 8

Trexall

Jazz Pharmaceuticals

Phase 2

3 9

Alkeran

Keppra

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Transplantation1 trial

Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)

Completed·UUniversity of Liverpool·N/A·NCT01186224·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Plerixafor and G-CSF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plerixafor and G-CSF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plerixafor and G-CSF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Liverpool company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Liverpool

Plerixafor and G-CSF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Transplantation1 trial

References

Drug Info

Quick Facts

Related News